Theravance Biopharma Inc (NASDAQ:TBPH) currently has a daily average trading volume of 373.05K but it saw 2056947 shares traded in last market. With a market cap of 425.73M USD, the company’s current market price of $8.84 came rising about 4.74 while comparing to the previous closing price of $8.44. In past 52 weeks, the stock remained buoying in the range of price level as high as $11.98 and as low as $8.21.
Taking a look at 20-day trading activity of Theravance Biopharma Inc (TBPH) gives us an average price of $9.28, while its current price level is -26.21% below from 52-week high level whereas it is 7.67% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $9.07 while that of 200 days or SMA-200 reads an average of $9.60. A closer look into the stock’s movement over the week reveals that its volatility is standing at 4.51% during that period while stretching the period over a month that decreases to 4.42%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 44.48 which implies that the stock is in neutral territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the BTIG Research which initiated the stock as “Buy” in its note to investors issued on April 12, 2024, recommending a price target of $21 for it. SVB Leerink also issued its recommendations for the stock as it initiated the price target for the stock is $12.
Over the week, TBPH’s stock price is moving -3.60% down while it is -2.86% when we observe its performance for the past one month. Year-to-date it is -21.35% down and over the past year, the stock is showing a downside performance of -19.71%.
The latest quarterly earnings report issued by the company reported quarterly earnings per share (EPS) of -0.35 beaten by the consensus estimate of -0.26 for the same. In next quarter, company is expected to be making quarterly sales of $15.6M as analysts are expecting the sales for current fiscal year at $71.1M and seeing the company making $83.2M in sales next year. Moreover, analysts are in estimates of $13.96M for current-quarter revenue.
Currently, Theravance Biopharma Inc’s total number of outstanding shares is 48.09M. Company’s return on investment (ROI) stands at -21.37% and return on equity (ROE) at -16.86%. Stock’s beta reads 0.36. Stock has a price to book (P/B) ratio of 2.00 while price to sale or P/S ratio amounts to 7.41. Its return on asset (ROA) is -11.16% on average.
